Category Archives: antidepressants

A review of two new books that attack the DSM-5, psychiatry’s “bible”

Share I reviewed two books now circulating about the DSM and the current controversy over the DSM-5 for The American Scholar — see review here. The two books are The Book of Woe: The DSM and the Unmaking of Psychiatry by … Continue reading

Posted in antidepressants, antipsychotic drugs, conflicts of interest, drug marketing, FDA, pharmaceutical industry, prescription drug abuse, scientific misconduct | Tagged , , , , , , , , | Leave a comment

Plot twists in Soderbergh’s new movie Side Effects strain belief

Share I went to see Steven Soderbergh’s new film, Side Effects, with anticipation and dread. The movie, after all, carries the same name as my 2008 book, Side Effects and from what I could tell of the trailers, its plot … Continue reading

Posted in antidepressants, drug marketing, FDA, pharmaceutical industry, prescription drug abuse, university industry collaboration | Tagged , , , , , , , , | 2 Comments

Why West Virginia has second highest rate of prescription drug overdoses in the nation

Share Did you know that West Virginia has the second highest rate of deaths from prescription drug overdoses in the country? I didn’t, until I moved to the Mountain State to live and work and became curious as to what … Continue reading

Posted in antidepressants, antipsychotic drugs, drug marketing, health care costs, patient care, pharmaceutical industry, prescription drug overdoes, public health | Tagged , , , , , , , , | 5 Comments

Martin Keller, principal investigator of Paxil study 329, retires from Brown University

Share I just learned that Dr. Martin Keller, principal investigator of the controversial Paxil study 329, has retired from his position as a professor of psychiatry at Brown University — see here. As Pharmalot notes, Keller quietly retired June 30 in … Continue reading

Posted in antidepressants, clinical trials, conflicts of interest, drug marketing, ghostwriting, pharmaceutical industry, scientific journal retractions, scientific misconduct | Tagged , , , , , | 2 Comments

Calls for action against authors of controversial Paxil study are getting louder

Share In the wake of GlaxoSmithKline’s record-breaking $3 billion settlement with the U.S. Department of Justice, a number of psychiatrists and researchers have redoubled their efforts to get Paxil study 329 retracted. As mentioned here and in other news accounts, the … Continue reading

Posted in antidepressants, clinical trials, conflicts of interest, drug marketing, ghostwriting, National Institutes of Health, pharmaceutical industry, scientific journal retractions, scientific misconduct, university industry collaboration | Tagged , , , , , , , | 2 Comments

Why academic researchers involved in fraudulent Paxil study escape scrutiny

Share The Chronicle of Higher Education this week ponders why various universities have taken no action against the academic researchers who co-authored the notorious Paxil study that formed the crux of GlaxoSmithKline’s recent $3 billion settlement with the Department of … Continue reading

Posted in antidepressants, clinical trials, National Institutes of Health, pharmaceutical industry, scientific journal retractions, scientific misconduct, university industry collaboration | Tagged , , , , , | 3 Comments

New York AG’s office should take a bow for GlaxoSmithKline’s record-breaking fine

Share I was glad to see that the New York Times‘ reporters covering GlaxoSmithKline’s $3 billion settlement tipped their hat to former New York Attorney General Eliot Spitzer. After all, it was his crew and specifically a pioneering attorney by … Continue reading

Posted in antidepressants, antipsychotic drugs, clinical trials, drug marketing, patient care, pharmaceutical industry, scientific journal retractions, scientific misconduct, suicide rates, whistleblowing | Tagged , , , , , , , | 4 Comments

Institute of Medicine report concludes that the FDA is not doing adequate job of assessing drug benefits and risks

Share Two weeks ago, I headlined my blog with this question: Is the FDA violating its own mandate to approve safe drugs? Four days later, the national Institute of Medicine (IOM) released a 233-page report concluding that FDA’s current approach … Continue reading

Posted in antidepressants, clinical trials, drug marketing, FDA, media coverage, National Institutes of Health, patient care, pharmaceutical industry, Uncategorized | Tagged , , , , , , , | 1 Comment

Is the FDA violating its own mandate to approve safe drugs?

Share Is the Food and Drug Administration violating its own mandate to approve safe drugs? That was the question that Donald Light, co-author of The Risk for Prescription Drugs and a long-time medical sociologist, posed at a talk yesterday at … Continue reading

Posted in antidepressants, biotech industry, clinical trials, continuing medical education, drug marketing, FDA, health care costs, medical devices, patient care, pharmaceutical industry, scientific misconduct, suicide rates, Uncategorized | Tagged , , , , , , , , , | 2 Comments

How drug companies continue to hide the true story of Tamiflu and other drugs from the American public

Share I’ve been reading Dr. David Healy’s new book, Pharmageddon, and while some of it may seem like old news, I was struck by his fresh analysis of how the pharmaceutical industry has turned the original purpose of clinical trials … Continue reading

Posted in antidepressants, antipsychotic drugs, clinical trials, drug marketing, FDA, health care costs, patient care, pharmaceutical industry, scientific misconduct | Tagged , , , , , , , , | 1 Comment